Generational Winner or Value Trap? Novo Nordisk Stock Explained скачать в хорошем качестве

Generational Winner or Value Trap? Novo Nordisk Stock Explained

Novo Nordisk has sold off over 60% as they faced multiple headwinds from competition, the FDA placing their key ingredient on the shortage list, to manufacturing issues. However, Novo Nordisk came out with a blockbuster drug for a market that is barely penetrated. In this video we break down the GLP1 market and go into depth into what happened with them and potential future growth opportunities. I worked at Goldman Sachs and an investment fund that managed hundreds of billions of dollars. In this channel I will teach you everything I know, including how to analyze a business, how to invest, the differences between bad and good businesses, and other finance topics. Follow us to learn 1) how to become a better investor and 2) how to analyze and understand business! ~*~ Chapters 0:00 — Blockbuster Success 1:00 — Setbacks 2:51 — The Incretin Market 9:56 — Why Down 60% Still? 12:28 — Upside 18:05 — New Threats 21:41 — Other Risks ~*~*~*~*~*~ Drew Cohen runs an investment research firm that caters to professional investor and hedge funds. You can find out more about it at www.SpeedwellResearch.com Drew also has a podcast with Speedwell Research called The Synopsis. The Synopsis is aimed toward professional investors and covers in-depth specific publicly traded companies. Follow the Podcast on Spotify here: https://open.spotify.com/show/3lGqHRK... Follow the Podcast on Apple here: https://podcasts.apple.com/us/podcast... ~*~*~*~*~*~ Nothing here is financial advice. See channel disclaimers. ~*~*~*~*~*~ #investing #stockmarket #finance